Prostate cancer (PC), counting for more than 1 million new cases per year and causing 375,304 deaths in 2020 worldwide, has attracted a lot of attention during the recent years with increasing morbidity and mortality. It is the second most common malignancy (after lung cancer) in men and a major cause of cancer deaths worldwide. In 1940s, the therapeutic effect of gonadal testosterone deprivation has been demonstrated by Huggins and Hodges. Since then, hormonal therapy has been the backbone of the treatment for advanced prostate cancer. From depriving the gonadal of testosterone, to blocking the production of adrenal and other extragonadal androgens, to the latest regime that directly binds and inhibits the androgen receptor, hormonal therapy has advanced greatly over the years. In the last few years, novel hormone therapy strategies, e.g. abiraterone, enzalutamide, apalutamide, darolutamide and so on, have been approved and shown excellent clinical efficacy.
In this Research topic, we hope to provide an overview of what is known about the latest advances in hormone therapy for prostate cancer and to highlight new therapies, clinical efficacy, adverse reactions and mechanisms. This would help to identify therapeutic approaches to improve the clinical efficacy.
This Research Topic aims to delineate advances in hormone therapy for prostate cancer. It will cover a spectrum of research interests that draw a holistic view to reveal the novel hormone therapy strategies for advanced prostate cancer, focusing on clinical efficacy and mechanisms of novel hormone therapy drugs, as well as side effects. Original research and reviews covering hormone therapy for prostate cancer are welcomed.
Subtopics of interest include, but are not limited to:
• Current status and research progress of hormone therapy for prostate cancer
• New advances in the targets and molecular mechanisms of new hormone drugs in the treatment of prostate cancer
• Molecular mechanism of hormone therapy leading to drug resistance in prostate cancer
• Endocrine and metabolic consequences of long-term hormone treatment in prostate cancer.
Prostate cancer (PC), counting for more than 1 million new cases per year and causing 375,304 deaths in 2020 worldwide, has attracted a lot of attention during the recent years with increasing morbidity and mortality. It is the second most common malignancy (after lung cancer) in men and a major cause of cancer deaths worldwide. In 1940s, the therapeutic effect of gonadal testosterone deprivation has been demonstrated by Huggins and Hodges. Since then, hormonal therapy has been the backbone of the treatment for advanced prostate cancer. From depriving the gonadal of testosterone, to blocking the production of adrenal and other extragonadal androgens, to the latest regime that directly binds and inhibits the androgen receptor, hormonal therapy has advanced greatly over the years. In the last few years, novel hormone therapy strategies, e.g. abiraterone, enzalutamide, apalutamide, darolutamide and so on, have been approved and shown excellent clinical efficacy.
In this Research topic, we hope to provide an overview of what is known about the latest advances in hormone therapy for prostate cancer and to highlight new therapies, clinical efficacy, adverse reactions and mechanisms. This would help to identify therapeutic approaches to improve the clinical efficacy.
This Research Topic aims to delineate advances in hormone therapy for prostate cancer. It will cover a spectrum of research interests that draw a holistic view to reveal the novel hormone therapy strategies for advanced prostate cancer, focusing on clinical efficacy and mechanisms of novel hormone therapy drugs, as well as side effects. Original research and reviews covering hormone therapy for prostate cancer are welcomed.
Subtopics of interest include, but are not limited to:
• Current status and research progress of hormone therapy for prostate cancer
• New advances in the targets and molecular mechanisms of new hormone drugs in the treatment of prostate cancer
• Molecular mechanism of hormone therapy leading to drug resistance in prostate cancer
• Endocrine and metabolic consequences of long-term hormone treatment in prostate cancer.
